Research Analysts Set Expectations for CalciMedica, Inc.’s FY2023 Earnings (NASDAQ:CALC)

CalciMedica, Inc. (NASDAQ:CALCFree Report) – Equities research analysts at HC Wainwright issued their FY2023 earnings per share estimates for shares of CalciMedica in a research note issued on Monday, January 29th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($14.64) per share for the year. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for CalciMedica’s current full-year earnings is ($8.23) per share. HC Wainwright also issued estimates for CalciMedica’s Q4 2023 earnings at ($0.86) EPS, Q1 2024 earnings at ($0.52) EPS, Q2 2024 earnings at ($0.59) EPS, Q3 2024 earnings at ($0.65) EPS, Q4 2024 earnings at ($0.65) EPS, FY2024 earnings at ($2.42) EPS, FY2025 earnings at ($2.16) EPS, FY2026 earnings at ($1.70) EPS, FY2027 earnings at ($1.24) EPS and FY2028 earnings at ($0.27) EPS.

Separately, Oppenheimer reiterated an “outperform” rating and issued a $14.00 price target on shares of CalciMedica in a research report on Monday, November 13th.

View Our Latest Stock Report on CALC

CalciMedica Stock Performance

Shares of CALC stock opened at $7.23 on Wednesday. The stock’s fifty day simple moving average is $3.75 and its 200 day simple moving average is $3.24. CalciMedica has a twelve month low of $1.00 and a twelve month high of $8.59.

CalciMedica (NASDAQ:CALCGet Free Report) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.32.

Insider Buying and Selling at CalciMedica

In related news, major shareholder Sanderling Venture Partners Vi purchased 243,356 shares of CalciMedica stock in a transaction on Tuesday, January 23rd. The shares were purchased at an average price of $3.70 per share, for a total transaction of $900,417.20. Following the transaction, the insider now owns 946,744 shares of the company’s stock, valued at approximately $3,502,952.80. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other CalciMedica news, major shareholder Sanderling Venture Partners Vi bought 243,356 shares of the business’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were bought at an average price of $3.70 per share, for a total transaction of $900,417.20. Following the transaction, the insider now directly owns 946,744 shares in the company, valued at $3,502,952.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Fred A. Middleton bought 679,384 shares of the business’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were acquired at an average price of $3.70 per share, for a total transaction of $2,513,720.80. Following the transaction, the director now owns 946,744 shares in the company, valued at $3,502,952.80. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 936,286 shares of company stock worth $3,454,119. Insiders own 53.30% of the company’s stock.

Institutional Investors Weigh In On CalciMedica

Several institutional investors and hedge funds have recently made changes to their positions in CALC. Hudson Bay Capital Management LP bought a new stake in shares of CalciMedica during the 3rd quarter valued at about $432,000. BML Capital Management LLC acquired a new position in CalciMedica during the 2nd quarter worth approximately $356,000. Finally, Meritage Portfolio Management acquired a new position in CalciMedica during the 2nd quarter worth approximately $40,000. Institutional investors own 42.76% of the company’s stock.

About CalciMedica

(Get Free Report)

CalciMedica, Inc, a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases.

See Also

Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.